TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining relatively low systemic toxicity. The antitumor activity, different dosing sequences, and dosing regimens of TH-302 in combination with commonly used conventional chemotherapeutics were investigated in human tumor xenograft models.Methods Seven chemotherapeutic drugs (docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide) were tested in combination with TH-302 in eleven human xenograft models, including non-small cell lung cancer (NSCLC), colon cancer, prostate cancer, fibrosarcoma, melanoma, and pancreatic cancer.Results The antitumor activity of docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, and temozolomide was increased when combined with TH-302 in nine out of eleven models tested. Administration of TH-302 2-8 h prior to the other chemotherapeutics yielded superior efficacy versus other sequences tested. Simultaneous administration of TH-302 and chemotherapeutics increased toxicity versus schedules with dosing separations. In a dosing optimization study, TH-302 administered daily at 50 mg/kg intraperitoneally for 5 days per week in the H460 NSCLC model showed the optimal response with minimal toxicity.Conclusions TH-302 enhances the activity of a wide range of conventional anti-neoplastic agents in a broad panel of in vivo xenograft models. These data highlight in vivo effects of schedule and order of drug administration in regimen efficacy and toxicity and have relevance to the design of human regimens incorporating TH-302.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the HAP evofosfamide (also known as TH-302) was reported to enhance the anticancer activity of chemotherapy drugs in mouse xenograft models of various cancer types, including CRC [216].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Major reasons for hypoxic tumor tissue resistance to chemotherapy include their distance from blood vessels and slower rate of proliferation [4, 26].”
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Doxorubicin is a poor tissue penetrator, and multiple previous studies have documented its inability to reach the hypoxic tumor compartment efficiently [28, 31].”
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“Hypoxic regions are common in tumors and contribute to malignant progression, metastasis and often resistance to both chemotherapy and radiotherapy [12, 43].”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240 · cited 1×
“The magnitude of tumor hypoxia measured in patients’ tumor tissue correlates with reduced survival [40].”
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686 · cited 1×
“The faster tumor regrowth kinetics that we observed with doxorubicin, cisplatin, irinotecan, and gemcitabine may be due to the selective sparing of stem cells in the hypoxic regions of xenografts [22, 39].”
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499 · cited 2×
“, doxorubicin and mitoxantrone [31, 38]; others exhibit low activity on slowly proliferating cells, e.”
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380 · cited 1×
“Hypoxia-activated compounds that have progressed to clinical trials for the treatment of cancer include tirapazamine [32], AQ4N [29], PR-104 [17], and TH-302 [41].”
Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
Duan, J.-X., Jiao, H., Kaizerman, J., Stanton, T., Evans, J. W., Lan, L., Lorente, G., Banica, M., Jung, D., Wang, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701028q · Cited by 239 · cited 2×
“TH-302 is more potent under hypoxic conditions versus aerobic conditions in cancer cell lines in vitro [8, 14, 27] and specifically targets hypoxic tumor cells in xenograft tumors in vivo [35].”
Self-citationTargeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230 · cited 1×
“Major reasons for hypoxic tumor tissue resistance to chemotherapy include their distance from blood vessels and slower rate of proliferation [4, 26].”
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0634 · Cited by 203 · cited 1×
“TH-302 is more potent under hypoxic conditions versus aerobic conditions in cancer cell lines in vitro [8, 14, 27] and specifically targets hypoxic tumor cells in xenograft tumors in vivo [35].”
Self-citationHypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Yokoi, K., & Fidler, I. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0488 · Cited by 199 · cited 1×
“Hypoxic cells have also demonstrated resistance to the cytotoxic effects of gemcitabine [45].”
Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190 · cited 3×
“TH-302 is more potent under hypoxic conditions versus aerobic conditions in cancer cell lines in vitro [8, 14, 27] and specifically targets hypoxic tumor cells in xenograft tumors in vivo [35].”
Self-citationHuber, P. E., Bischof, M., Jenne, J., Heiland, S., Peschke, P., Saffrich, R., Gröne, H.-J., Debus, J., Lipson, K. E., & Abdollahi, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1668 · Cited by 185
Weiss, G. J., Infante, J. R., Chiorean, E. G., Borad, M. J., Bendell, J. C., Molina, J. R., Tibes, R., Ramanathan, R. K., Lewandowski, K., Jones, S. F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3425 · Cited by 154
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Hu, J., Handisides, D. R., Van Valckenborgh, E., De Raeve, H., Menu, E., Vande Broek, I., Liu, Q., Sun, J. D., Van Camp, B., Hart, C. P., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269126 · Cited by 152 · cited 1×
“TH-302 is more potent under hypoxic conditions versus aerobic conditions in cancer cell lines in vitro [8, 14, 27] and specifically targets hypoxic tumor cells in xenograft tumors in vivo [35].”
Self-citationTumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie, M. J., & Brown, J. M. (1993) · PubMed · Cited by 143
Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy
Li, X., Carlin, S., Urano, M., Russell, J., Ling, C. C., & O’Donoghue, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4353 · Cited by 140 · cited 2×
“H460 cells were implanted in the pleural cavity of nude mice to obtain an orthotopic/metastatic tumor model, following the method of Kraus-Berthier and co-workers [24].”
MethodWilliamson, S. K., Crowley, J. J., Lara, P. N., McCoy, J., Lau, D. H. M., Tucker, R. W., Mills, G. M., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3771 · Cited by 129 · cited 1×
“Combining a normoxic compartment-selective conventional chemotherapeutic with a hypoxia compartmentselective agent, such as TH-302, should provide a complementary approach to eliminate all tumor cell subpopulations, without a corresponding increase in systemic toxicity [6, 30, 42].”
Jameson, M. B., Rischin, D., Pegram, M. D., Gutheil, J. C., Patterson, A. V., Denny, W. A., & Wilson, W. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1188-1 · Cited by 102 · cited 1×
“Hypoxia-activated compounds that have progressed to clinical trials for the treatment of cancer include tirapazamine [32], AQ4N [29], PR-104 [17], and TH-302 [41].”
Kallman, R. F., & Dorie, M. J. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90080-5 · Cited by 97 · cited 1×
“It is possible that administration of the conventional chemotherapeutic before TH-302 may cause re-oxygenation of the hypoxic compartment by the conventional chemotherapeutic activity on the normoxic cells resulting in a reduction of their consumption of oxygen [7, 19].”
Tannock, I. F. (1982) · PubMed · Cited by 93
Grau, C., & Overgaard, J. (1988) · Radiotherapy and Oncology · doi:10.1016/0167-8140(88)90225-3 · Cited by 91 · cited 2×
“Grau and Overgaard showed that cisplatin produced little or no effect on hypoxic cells in tumors, despite killing a large proportion of normoxic tumor cells [10].”
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., Okuno, S. H., Lorente, G., Kroll, S., Langmuir, V. K., & Chawla, S. P. (2011) · Oncology · doi:10.1159/000327739 · Cited by 81 · cited 1×
“There is no evidence for TH-302 drug–drug interaction in the clinical setting [3, 9].”
Self-citation(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1163 · Cited by 81 · cited 1×
“Combining a normoxic compartment-selective conventional chemotherapeutic with a hypoxia compartmentselective agent, such as TH-302, should provide a complementary approach to eliminate all tumor cell subpopulations, without a corresponding increase in systemic toxicity [6, 30, 42].”
Microregional Effects of Gemcitabine in HCT-116 Xenografts
Huxham, L. A., Kyle, A. H., Baker, J. H. E., Nykilchuk, L. K., & Minchinton, A. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0986 · Cited by 79
Li, X., & O’Donoghue, J. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.037 · Cited by 70 · cited 1×
“Like others, we have observed high hypoxic fractions in micrometastases [25, 34].”
Dorie, M. J., & Brown, J. M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050584 · Cited by 65 · cited 1×
“Combining a normoxic compartment-selective conventional chemotherapeutic with a hypoxia compartmentselective agent, such as TH-302, should provide a complementary approach to eliminate all tumor cell subpopulations, without a corresponding increase in systemic toxicity [6, 30, 42].”
Trédan, O., Garbens, A., Lalani, A. S., & Tannock, I. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0676 · Cited by 60 · cited 1×
“, doxorubicin and mitoxantrone [31, 38]; others exhibit low activity on slowly proliferating cells, e.”
Papadopoulos, K. P., Goel, S., Beeram, M., Wong, A., Desai, K., Haigentz, M., Milián, M. L., Mani, S., Tolcher, A., Lalani, A. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0483 · Cited by 55 · cited 1×
“Hypoxia-activated compounds that have progressed to clinical trials for the treatment of cancer include tirapazamine [32], AQ4N [29], PR-104 [17], and TH-302 [41].”
Kraus‐Berthier, L., Jan, M., Guilbaud, N., Naze, M., Pierré, A., & Atassi, G. (2000) · PubMed · Cited by 53
Reoxygenation and rehypoxiation in the SCCVII mouse tumor
Kim, I. H., & Brown, J. M. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90444-8 · Cited by 51 · cited 1×
“Peculiar to this particular approach to cancer therapy, one of the agents could affect the compartmental specificity of the other agent, relative to single-agent administration [7, 10, 15, 21].”
Enhancement of Alkylating Agent Activity by SR-4233 in the FSaIIC Muraine Fibrosarcoma
Holden, S. A., Teicher, B. A., Ara, G., Herman, T. S., & Coleman, C. N. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.3.187 · Cited by 42 · cited 1×
“Specific drug combination regimens can be employed using different dosing sequences and schedules, leading to different efficacies and toxicities [11, 13, 33, 44].”
Harris, S. M., Mistry, P., Freathy, C., Brown, J. L., & Charlton, P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602403 · Cited by 33 · cited 1×
“Specific drug combination regimens can be employed using different dosing sequences and schedules, leading to different efficacies and toxicities [11, 13, 33, 44].”
Jung, D. T., Lin, L., Jiao, H., Cai, X., Duan, J.-X., & Matteucci, M. D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1741-6 · Cited by 22 · cited 1×
“But notably, the plasma half-life of TH-302 in mice is short (8–10 min), and therefore, after the 4 h delay, plasma levels of TH-302 are very low [18].”
Self-citationYamada, H., Uchida, N., Maekawa, R., & Yoshioka, T. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00614-0 · Cited by 20 · cited 1×
“Specific drug combination regimens can be employed using different dosing sequences and schedules, leading to different efficacies and toxicities [11, 13, 33, 44].”
Bhattacharya, A., Tóth, K., Durrani, F. A., Cao, S., Slocum, H. K., Chintala, S., & Rustum, Y. M. (2008) · Neoplasia · doi:10.1593/neo.08424 · Cited by 17 · cited 2×
“In the A253 human head and neck squamous cell cancer xenograft, 5- to 7-fold less irinotecan was present in hypoxic regions versus well-vascularized regions of the same tumor [2].”
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.
Batchelder, R. M., Wilson, W. R., Hay, M. P., & Denny, W. A. (1996) · Europe PMC (PubMed Central) · Cited by 16
Development of Hypoxia in a Preclinical Model of Tumor Micrometastases
Simonsen, T. G., Gaustad, J., & Rofstad, E. K. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.045 · Cited by 14 · cited 1×
“Like others, we have observed high hypoxic fractions in micrometastases [25, 34].”
Reoxygenation in the rif-1 tumor after chemotherapy
Dorie, M. J., & Kallman, R. F. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90684-a · Cited by 14 · cited 3×
“It is possible that administration of the conventional chemotherapeutic before TH-302 may cause re-oxygenation of the hypoxic compartment by the conventional chemotherapeutic activity on the normoxic cells resulting in a reduction of their consumption of oxygen [7, 19].”
Repopulation of Tumour Cells Following Irradiation with X-rays or Low Energy Neutrons
Tsunemoto, H., Andō, K., Koike, S., & Urano, M. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550281 · Cited by 13 · cited 1×
“The faster tumor regrowth kinetics that we observed with doxorubicin, cisplatin, irinotecan, and gemcitabine may be due to the selective sparing of stem cells in the hypoxic regions of xenografts [22, 39].”
Saucier, J. M., Jiang, Y. L., Gaikwad, A., Coleman, R. L., Wolf, J. K., & Smith, J. A. (2007) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155207077948 · Cited by 11 · cited 1×
“Specific drug combination regimens can be employed using different dosing sequences and schedules, leading to different efficacies and toxicities [11, 13, 33, 44].”
1226 Multi-arm Phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed
Borad, M. J., Infante, J. R., Mita, A. C., Chiorean, E. G., Mendelson, D. S., Vlahovic, G., Wilding, G., Langmuir, V. K., & Kroll, S. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)70438-0 · Cited by 3 · cited 1×
“There is no evidence for TH-302 drug–drug interaction in the clinical setting [3, 9].”
Cited by
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
“For instance, it has been observed that a hypoxia-activated pro-drug designated as TH-302, which selectively targets hypoxic regions of solid tumours in combination with conventional chemotherapeutic drugs such as gemcitabine-induced greater anti-tumoral effects on diverse human tumour xenograft models including pancr…”
BackgroundMejia Oneto, J. M., Khan, I., Seebald, L., & Royzen, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00150 · Cited by 215
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
“TH-302, a hypoxia-induced pro-drug (HAP), functions as a DNA alkylating agent to induce damage and cell death [450].”
BackgroundBorad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Metadata
- Authors
- Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., & Hart, C. P.
- Affiliations
- Threshold Pharmaceuticals (United States) (US)
- University of Arizona (US)
- Corresponding author
- Hart, Charles P.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2012-03-02
- Volume
- 69
- Issue
- 6
- Pages
- 1487-1498
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC3985381
- OpenAlex
- W2087565365
- Cited by
- 113
- References
- 45
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 8 · 2016: 17 · 2015: 15 · 2014: 9 · 2013: 13 · 2012: 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50 CA95060, R01CA125627, P50CA095060, P30CA023074)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- TH-302, hypoxia-activated prodrug, tumor hypoxia, combination chemotherapy, dosing regimen, dosing regimen optimization, chemotherapy toxicity, non-small cell lung cancer, xenograft models, docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, temozolomide
- MeSH terms
- Pemetrexed, Docetaxel, Irinotecan, Gemcitabine, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Cisplatin, Deoxycytidine, Drug Evaluation, Preclinical, Glutamates, Guanine, Humans, Nitroimidazoles, Phosphoramide Mustards, Prodrugs, Cell Hypoxia, Mice, SCID, Xenograft Model Antitumor Assays, Taxoids, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.